Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

AbbVie’s deal flop and NFL high-profile draft busts have a lot in common.

STAT gathered reactions from leaders across biotech and pharma about what the new Trump era could mean for them.

WASHINGTON — Newly empowered Republican leadership in the White House and in Congress will likely bring some good news and ...

Revenue: US$2.73m (down 33% from 3Q 2023). Net loss: US$162.0m (loss narrowed by 8.5% from 3Q 2023). US$0.86 loss per share ...

Investors increased their allocations to pharmaceuticals, banks, and industrials in November, according to the latest BofA ...

Ascendis Pharma (ASND) has released an update. Ascendis Pharma A/S has structured its capital to enable significant growth opportunities, with ...

With the respiratory illness season starting up in earnest, Vicks has reclaimed the top Rx and over-the-counter (OTC) pharma ...

The IPO of Onyx Biotec Limited was fully subscribed for within hours of its Wednesday, November 13 launch. There was a high ...

Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...

Urogen's UGN-102 presents a $5B market opportunity for bladder cancer treatment, despite risks. Read more about URGN stock ...

The deal is expected to provide SPIMACO with a significant opportunity to strengthen its product portfolio, enhance its ...